Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 June 2007

Ann Rheum Dis. Published Online First: 5 April 2007. doi:10.1136/ard.2006.066001
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ard.2006.066001v1
66/6/764    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farkouh, M. E.
Right arrow Articles by Abramson, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farkouh, M. E.
Right arrow Articles by Abramson, S. B.

Extended Report

Cardiovascular outcomes in high-risk patients with osteoarthritis treated with Ibuprofen, Naproxen, or Lumiracoxib

Michael E. Farkouh 1*, Jeffrey D. Greenberg 2, Raban V. Jeger 3, Krishnan Ramanathan 3, Freek W. A. Verheugt 4, James H. Cheseboro 5, Howard Kirshner 6, Judith S. Hochman 3, Christine L. Lay 7, Sean Ruland 8, Bernhard Mellein 9, Patrice T. Matchaba 10, Valentin Fuster 1 and Steven B. Abramson 2

1 Mount Sinai School of Medicine, United States
2 NYU Hospital for Joint Diseases, United States
3 NYU School of Medicine, United States
4 University Medical Center, Nijmegen, United States
5 Mayo Clinic, United States
6 Vanderbilt University School of Medicine, United States
7 St. Luke's-Roosevelt Hospital Center, United States
8 University of Chicago at Illinois, United States
9 Novartis Pharmaceuticals, Switzerland
10 Novartis Pharmaceuticals, United States

* To whom correspondence should be addressed. E-mail: michael.farkouh{at}mssm.edu.

Accepted 21 January 2007


*  Abstract

Background: Evidence suggests that both selective cyclooxygenase (COX)-2 inhibitors and non-selective NSAIDs increase the risk of cardiovascular (CV) events. However, evidence from prospective studies of currently available COX-2 inhibitors and non-selective NSAIDs is lacking in high CV risk patients taking aspirin.

Methods: The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of 18,325 osteoarthritis patients comprised 2 parallel sub- studies, comparing lumiracoxib (COX-2 inhibitor) to either ibuprofen or naproxen. We performed a post hoc analysis stratified by baseline cardiovascular risk, treatment assignment, and low-dose aspirin use. The primary composite endpoint was cardiovascular mortality, nonfatal myocardial infarction, and stroke at 1 year; a secondary endpoint was the development of congestive heart failure (CHF).

Results: In high risk patients among aspirin users, patients in the ibuprofen sub-study had more primary events with ibuprofen than lumiracoxib (2.14% vs. 0.25%, p=0.038), whereas in the naproxen sub-study rates were similar for naproxen and lumiracoxib (1.58% vs. 1.48%, p=0.899). High risk patients not taking aspirin had fewer primary events with naproxen versus lumiracoxib (0% vs. 1.57%, p=0.027), but not ibuprofen versus lumiracoxib (0.92% vs. 0.80%, p=0.920). Overall, CHF developed more often with ibuprofen than lumiracoxib (1.28% vs. 0.14%; p=0.031), whereas no difference existed between naproxen and lumiracoxib.

Conclusions:These data suggest that ibuprofen may confer an increased risk of thrombotic and CHF events relative to lumiracoxib among aspirin users at high cardiovascular risk. Our study indicates that naproxen may be associated with lower risk relative to lumiracoxib among non-aspirin users. Our data should be interpreted as hypothesis-generating.


Keywords: COX-2 inhibitors, anti-inflammatory agents, non-steroidal, aspirin, coronary disease, osteoarthritis




This article has been cited by other articles:


Home page
Clin. Chem.Home page
J. L. Januzzi Jr
Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter
Clin. Chem., July 1, 2008; 54(7): 1107 - 1109.
[Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
C. M. Ferrario
Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?
Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 75 - 78.
[PDF]


Home page
HeartHome page
Arthritis drugs are hazardous for high risk patients
Heart, April 1, 2008; 94(4): 403 - 403.
[Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
A. Aneja and M. E. Farkouh
Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 53 - 66.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism